Mo1560 Validity of Endoscopic Submucosal Dissection for Early Gastric Cancer in Super-Elderly Patients With Concomitant Diseases

group performance status (ECOG-PS) was 0 in 3 patients, 1 in 11 patients, 2 in 11 patients and 3 in 3 patients. The main indications for stent placement were pancreatic adenocarcinoma with duodenal infiltration in 13 (46.4%) patients, gastric adenocarcinoma in 7 (25%), cholangiocarcinoma in 3 (10.7%), duodenal adenocarcinoma in 3 (10.7%) and 1 (3.6%) in each of small bowel adenocarcinoma and gall bladder adenocarcinoma. Technical success rate for stent deployment was 100% and oral intake was possible in all (100%) of the stented patients with 93% of patients being capable of eating at least a mechanical soft diet. There were no sedation related adverse events and procedure related complications including perforation and haemorrhage. Among late complications there were 3 (10.7%) stent obstructions related to tumour ingrowth requiring re-insertion of stents and 1 (3.5%) biliary obstruction requiring biliary stent insertion. The mean survival from stent placement to death was 111 days (range 9-438). Three patients (11%) were still alive after an average of 250 days post stent deployment. 30 days mortality was 6 (21%) but this was related to advance malignant disease rather related to endoscopic stent placement. Conclusion: In our experience enteral stenting is a safe palliative procedure and it improves quality of life by relieving gastrointestinal obstruction and restoration of enteral tract for nutrition in all successfully stented cases. Enteral stenting contributed towards an average survival of around four months and hence must be considered in this high risk group of patients.